Skip to main content
Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia in Mice Using Novel RyR2-Modifying Drugs
International Journal of Cardiology
  • Na Li, Baylor College of Medicine
  • Qiongling Wang, Baylor College of Medicine
  • Martha Sibrian-Vazquez, Portland State University
  • Robert C. Klipp, Portland State University
  • Julia O. Reynolds, Baylor College of Medicine
  • Tarah A. Word, Baylor College of Medicine
  • Larry Scott, Jr., Baylor College of Medicine
  • Guy Salama, University of Pittsburgh
  • Robert M. Strongin, Portland State University
  • Jonathan J. Abramson, Portland State University
  • Xander H. T. Wehrens, Baylor College of Medicine
Document Type
Publication Date
Rationale Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal arrhythmic disorder caused by mutations in the type-2 ryanodine receptor (RyR2). Mutant RyR2 cause abnormal Ca2 + leak from the sarcoplasmic reticulum (SR), which is associated with the development of arrhythmias. Objective To determine whether derivatives of tetracaine, a local anesthetic drug with known RyR2 inhibiting action, could prevent CPVT induction by suppression of RyR2-mediated SR Ca2 + leak. Methods and results Confocal microscopy was used to assess the effects of tetracaine and 9 derivatives (EL1–EL9) on spontaneous Ca2 + sparks in ventricular myocytes isolated from RyR2-R176Q/+ mice with CPVT. Whereas each derivative suppressed the Ca2 + spark frequency, derivative EL9 was most effective at the screening dose of 500 nmol/L. At this high dose, the Ca2 + transient amplitude was not affected in myocytes from WT or R176Q/+ mice. The IC50 of EL9 was determined to be 13 nmol/L, which is about 400 × time lower than known RyR2 stabilizer K201. EL9 prevented the induction of ventricular tachycardia observed in placebo-treated R176Q/+ mice, without affecting heart rate or cardiac contractility. Conclusions Tetracaine derivatives represent a novel class of RyR2 stabilizing drugs that could be used for the treatment of the potentially fatal disorder catecholaminergic polymorphic ventricular tachycardia.
Persistent Identifier
Citation Information
Li, N., Wang, Q., Sibrian-Vazquez, M., Klipp, R. C., Reynolds, J. O., Word, T. A., ... & Wehrens, X. H. (2016). Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. International Journal of Cardiology.